Cabozantinib, sold under the brand names Cometriq and Cabometyx among others, is an anti-cancer medication used to treat medullary thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma. It works as a tyrosine kinase inhibitor, targeting multiple pathways involved in tumor growth, angiogenesis, and metastasis. Cabozantinib is known for its ability to inhibit the MET, VEGFR, and RET pathways, making it a versatile treatment option for certain cancers.
Parent: Cabozantinib/ Cabozantinib (S)-Malate
Parent: Cabozantinib
Parent: Cabozantinib
Parent: Cabozantinib
Parent: Cabozantinib
Parent: Cabozantinib
Parent: Cabozantinib
Parent: Cabozantinib
Parent: Cabozantinib
Parent: Cabozantinib
Parent: Cabozantinib
Parent: Cabozantinib
Parent: Cabozantinib
During the production and storage of Cabozantinib, related compounds and impurities may form, which must be controlled to ensure the medication’s safety and efficacy. Regulatory guidelines specify permissible impurity levels for pharmaceutical formulations.
Key aspects of Cabozantinib-related compounds and impurities include:
Advanced analytical methods, such as High-Performance Liquid Chromatography (HPLC), are employed to detect and quantify Cabozantinib-related compounds and impurities, ensuring compliance with stringent quality standards.
Cabozantinib is not traditional chemotherapy. It is a targeted therapy known as a tyrosine kinase inhibitor (TKI) that works by blocking specific enzymes involved in cancer cell growth and spread.
Cabozantinib inhibits multiple tyrosine kinases, including MET, VEGFR, and RET, which are critical pathways involved in tumor growth, angiogenesis (formation of blood vessels that feed tumors), and metastasis.
The survival rate for Cabozantinib varies depending on the type and stage of cancer being treated. Clinical trials have demonstrated significant improvements in progression-free survival and overall survival in patients with advanced renal cell carcinoma and hepatocellular carcinoma.
Cabozantinib has shown success in treating specific cancers, with significant tumor shrinkage and delayed disease progression observed in clinical trials. Its effectiveness depends on the type of cancer and individual patient response.
